Therapeutic agent for keratoconjunctival disorder

Details Therapeutic agent for keratoconjunctival disorder Therapeutic agent for keratoconjunctival disorder

2004-10-29

2008-03-25

Hartley, Michael G. (Department: 1618)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S256000, C514S267000, C514S269000

Reexamination Certificate

active

07348329

ABSTRACT:
An object of the present invention is to discover a new medicinal use of 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiazolidine-2,4-dione and N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine. Both of the compounds exert an excellent improving effect on corneal disorder models and is useful as a therapeutic agent for a keratoconjunctival disorder such as dry eyes, corneal ulcer, keratitis, conjunctivitis, superficial punctate keratopathy, corneal epithelial defects, conjunctive epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis and filamentary keratitis.

REFERENCES:
patent: 5447946 (1995-09-01), Kuronu et al.
patent: 5885997 (1999-03-01), Lohray et al.
patent: 5886014 (1999-03-01), Fujita et al.
patent: 6372750 (2002-04-01), Lohray et al.
patent: 6573268 (2003-06-01), Lohray et al.
patent: 6780992 (2004-08-01), Lohray et al.
patent: 2007/0060628 (2007-03-01), Nakamura et al.
patent: 3-72227 (1991-11-01), None
patent: 8-231549 (1996-09-01), None
patent: 9-295970 (1997-11-01), None
patent: 11-130675 (1999-05-01), None
patent: 2001-39976 (2001-02-01), None
patent: 2002-515874 (2002-05-01), None
patent: 2002-220336 (2002-08-01), None
patent: 2002-255854 (2002-09-01), None
patent: 2003-509503 (2003-03-01), None
patent: WO 97/41097 (1997-11-01), None
patent: WO 01/21602 (2001-03-01), None
Hisashi Hosoya (Hisashi Hosotani), “Tonyobyosei Kakumakusho”, “Diabetic Kerathopathy”,The Journal of the Eye, 1996, 13(6), pp. 845-851.
Kazuko Kameyama, “Tonyobyo Gappeisho to Shiteno Ganbyohen”,Clinics&Drug Therapy, 2002, 21(11), pp. 1089 to 1092.
Yasuichiro Chikama, “Hen'ensei Kakumaku Johi Kasson”, “Diagnosis and Medical Treatment for Persistent Epithelial Defect”, Ganka, 2001, 43, pp. 1625 to 1631.
Japanese Review of Clinical Ophthalmology, 46, 738-743 (1992).
Chikako Katakami, “A New Treatment for Corneal Epithelial Defects Using Fibronectin, EGF and Hyaluronic Acid”,Ophthalmic Surgery, 5, 719-727 (1992).
U.S. Appl. No. 10/576,719 filed Apr. 20, 2006; Group Art Unit 1614; Confirmation No. 6306.

Affiliated with

Also associated with

Rating

Therapeutic agent for keratoconjunctival disorder does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic agent for keratoconjunctival disorder, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agent for keratoconjunctival disorder will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3971595